AN2 Therapeutics, Inc.

NasdaqGS:ANTX Stock Report

Market Cap: US$28.8m

AN2 Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ANTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 26SellUS$24,962Joshua EizenIndividual24,854US$1.01
06 Jan 26SellUS$9,332Sanjay ChandaIndividual9,251US$1.01
06 Jan 26SellUS$8,883Lucy DayIndividual8,807US$1.01
06 Jan 26SellUS$6,507Stephen PriorIndividual6,462US$1.01
04 Nov 25SellUS$872Stephen PriorIndividual765US$1.14
04 Nov 25SellUS$3,214Joshua EizenIndividual2,819US$1.14
17 Jun 25SellUS$3,118,800BML Capital Management, LLCCompany2,790,000US$1.12
02 Jun 25BuyUS$10,665Eric EasomIndividual10,000US$1.07
30 May 25SellUS$2,872,477BML Capital Management, LLCCompany2,532,000US$1.16
28 May 25BuyUS$10,133Margaret FitzPatrickIndividual8,610US$1.18
28 May 25SellUS$218,000BML Capital Management, LLCCompany200,000US$1.09

Insider Trading Volume

Insider Buying: ANTX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ANTX?
Owner TypeNumber of SharesOwnership Percentage
Public Companies927,2013.38%
Individual Insiders2,155,2067.87%
VC/PE Firms2,373,5008.66%
Hedge Funds4,244,22315.5%
Institutions8,425,58430.7%
General Public9,276,31033.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 63.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.3%
Coastlands Capital LP
2,815,900US$3.0m0%no data
8.66%
Adjuvant Capital, LP
2,373,500US$2.5m0%no data
5.21%
Almitas Capital LLC
1,428,323US$1.5m0%0.3%
4.73%
Eric Easom
1,296,762US$1.4m0%no data
4.51%
Mountain Group Capital, LLC
1,234,861US$1.3m0%100.0%
3.94%
The Vanguard Group, Inc.
1,080,070US$1.1m0%no data
3.38%
Brii Biosciences Limited
927,201US$973.6k0%no data
2.61%
Pfizer Venture Investments LLC
715,295US$751.1k0%0.25%
2.17%
Peapod Lane Capital LLC
593,396US$623.1k0.71%0.51%
2.06%
Stonepine Capital Management LLC
563,913US$592.1k3.57%0.31%
2.01%
Joseph Zakrzewski
551,418US$579.0k0%no data
1.68%
The Bank of Nova Scotia
459,194US$482.2k0%no data
1.67%
Landscape Capital Management, LLC
456,463US$479.3k-7.86%0.03%
1.54%
BMO Asset Management Corp.
422,077US$443.2k0%no data
1.41%
Bank of America Corporation
385,310US$404.6k-0.05%no data
1.37%
Aldebaran Capital, LLC
376,770US$395.6k-4.07%0.33%
1.24%
Renaissance Technologies LLC
338,600US$355.5k-12.2%no data
1.17%
BlackRock, Inc.
320,911US$337.0k0.51%no data
0.98%
Two Sigma Advisers, LP
267,900US$281.3k-0.63%no data
0.92%
Geode Capital Management, LLC
251,875US$264.5k1.01%no data
0.82%
Two Sigma Investments, LP
223,337US$234.5k-6.3%no data
0.7%
Morgan Stanley
190,770US$200.3k7.03%no data
0.32%
State Street Global Advisors, Inc.
87,002US$91.4k0%no data
0.27%
Gilbert Marks
75,309US$79.1k41.1%no data
0.24%
Rangeley Capital, LLC
65,000US$68.3k0%0.05%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/13 16:14
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AN2 Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas BuchananCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Joseph SchwartzLeerink Partners LLC